跳至主要内容
临床试验/NL-OMON39950
NL-OMON39950已完成不适用

The Surpass intracranial aneurysm embolization system pivotal trial to treat large or giant wide neck aneurysms - SCENT

Boston Biomedical Associates0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • age 19-80 years
  • subject has a single targeted intracranial aneurysm that:
  • - located in the internal carotid artery distribution up to the terminus
  • -is able to cross with a standard 0,014guide wire
  • -has a neck > 4mm or no discernible neck and an aneurysm size > 10mm

排除标准

  • - known allergy or contraindication to Aspirin, Clopidogrel/Plavix, heparin,local or general anesthesia.
  • - known history of life threathening allergy to contrast dye
  • - More than one intracranial aneurysm that requires treatment within 12 months
  • - unstable neurological deficit
  • - extra-cranial stenosis or parent vessel with stenosis > 50% in the area proximal to the aneurysm

研究者

发起方
Boston Biomedical Associates

相似试验

The Surpass intracranial aneurysm embolization... | 临床试验